Loading clinical trials...
Loading clinical trials...
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07516964 · Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, and more
NCT06529796 · Focal Segmental Glomerulosclerosis (FSGS)
NCT05955872 · Focal Segmental Glomerulosclerosis (FSGS)
The Kirklin Clinic of University Alabama Birmingham Hospital
Birmingham, Alabama
Investigational Drug Service Pharmacy UAB Hosptial
Birmingham, Alabama
Clinical Research Unit at UAB Hospital
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions